Interim metabolic tumor volume to predict response in diffuse large B-cell lymphoma.

Prioty Islam,Jordan Goldstein,Ila Sethi,Daniel Lee,Christopher R. Flowers

Interim metabolic tumor volume to predict response in diffuse large B-cell lymphoma.

2017

Prioty Islam
Jordan Goldstein
Ila Sethi
Daniel Lee
Christopher R. Flowers

7557Background: DLBCL is a heterogeneous disease with varied clinical outcomes following treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). [18F] fluorode...

Keywords:

Diffuse large B-cell lymphoma
Interim
Pathology
Medicine
Oncology
metabolic tumor volume
Doxorubicin
Rituximab
Internal medicine
Cyclophosphamide
Vincristine
Prednisone

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations